Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial
Van Vlierberghe, H.; Leroux-Roels, G.; Adler, M.et al.
2003 • In Journal of Viral Hepatitis, 10 (6), p. 460-466
[en] The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the hepatitis C virus (HCV) load and a better response rate. Naive chronically infected HCV patients (n = 454) were randomized into two arms to receive either induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily during a period of 8 weeks (arm A); or treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for a period of 8 weeks (arm B). After week 8, interferon treatment in both arms was 3 MU s.c. TIW for a total period of 12 months. In both arms, ribavirin (1000-1200 mg orally per day) was added at week 4. Induction treatment resulted in a higher virological response at week 8 of treatment (66%vs 47%; P < 0.01). However, response at the end of treatment and at 6 months follow-up was not different (53%vs 50%, 41%vs 33%). The occurrence of adverse events and the drop-out rate were similar in both arms. Although an early virological response is observed more frequently in the induction treatment, end of treatment response and sustained responses did not differ.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Vlierberghe, H.; Ghent University Hospital, > Gastroenterology and Hepatology
Leroux-Roels, G.; Ghent University Hospital > Clinical Chemistry
Adler, M.; ULB Erasme > Gastroenterology
Bourgeois, N.; ULB Erasme > Gastroenterology
Nevens, F.; KULeuven > Hepatology
Horsmans, Y.; Université Catholique de Louvain - UCL > Gastroenterology
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial
EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 31(Suppl 1): 3-8.
Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. Effect if interferon alfa on the dynamics of hepatitis C turnover in vivo. Hepatology 1996; 23: 366-371.
Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-107.
Zeuzem S. Favourable and disappointing lessons from viral kinetics. J Hepatol 2002; 37: 151-153.
Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
Zeuzem S, Lee JH, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156.
Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa 2a. Gastroenterology 2001; 120: 1438-1447.
Gnomon AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:28-35.
Di Marco V, Ferraro D, Almasio P et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepatitis 2002; 9: 354-359.
Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33(2): 419-423.
Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
McHuntchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28(6): 960-964.
Neumann AU, Dahari H, Conrad A, Planko S, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN alpha dual therapy effect on chronic hepatitis C. Hepatology 1999; 30: 309A.
Pawlotsky JM, Dahari H, Conrad A et al. Effect of intermittent interferon, daily IFN and IFN plus ribavirin induction therapy of hepatitis C virus genotype 1b replication kinetics and clearance. Hepatology 1998; 28: 288A.
Zeuzem Z, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252.
Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U. Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha treated patients with response or no response. Z Gastroenterol 2000; 38: 881-886.
Fried MW, Shiffman M, Sterling RK et al. A multicenter, randomized trial of daily high-dose interferon alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95: 3225-3229.
Layden TJ, Layden JE, Rajender Reddy K, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon does not improve sustained virological response in chronic hepatitis C. J Viral Hepatitis 2002; 9: 334-339.
Poynard T, Daurat V, Chevret S et al. A short induction regimen of interferon alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. J Viral Hepatitis 1999; 6: 381-386.
Ferenci P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
Carithers RL, Zeuzem S, Manns MP et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa 2b plus ribavirin. Hepatology 2000; 32: 317A.
Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roels G and the BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 911-916.
Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.
